Manning Paul B reported grant involving 2,189 derivative units of Candel Therapeutics, Inc. at $8.68 for $19.0k on Sep 30, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Director
DIR
Filed Oct 2, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$18,991.76Shares × reported price
Shares traded
2,189Stock Option (Right to Buy)
Price per share
$8.68Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
2,189Direct
Trade date
Sep 30, 2026Grant
Filed
Oct 2, 2026, 5:54 PM ET2-day reporting delay
Accession
0001193125-26-412654Code A · Transaction 235657
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

CADL price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
CADL · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +28%1w ago +11%1d ago +6.9%
Returns since7d −2.4%30d −18%90d180d1y

Footnotes in full

F1: This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant.